Back to top
more

Coherus Oncology, Inc. (CHRS)

(Delayed Data from NSDQ)

$1.61 USD

1.61
2,798,149

+0.08 (5.23%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $1.61 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (101 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Coherus Oncology (CHRS) delivered earnings and revenue surprises of -9.68% and +1.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2

by Zacks Equity Research

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of +100.00% and +593.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?

by Zacks Equity Research

Krystal Biotech (KRYS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -12.90% and 85.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -226.47% and 60.60%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fortrea Holdings Inc. (FTRE) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of -50% and 0.63%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of 8% and 35%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

RDY Q3 Earnings Match Estimates, Generics Revenues Rise Y/Y, Stock Down

by Zacks Equity Research

Dr. Reddy's stock falls on Q3 fiscal 2025 results, wherein earnings match estimates but revenues beat the same.

Zacks Equity Research

Here's Why You Should Add Dr. Reddy's Stock to Your Portfolio

by Zacks Equity Research

RDY enjoys a strong foothold in the global generics market due to its deep generic drugs pipeline. Its efforts to strengthen its biosimilars portfolio are commendable.

Zacks Equity Research

RDY Launches Loqtorzi Biosimilar in India for Nasopharyngeal Carcinoma

by Zacks Equity Research

Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or metastatic nasopharyngeal carcinoma.

Zacks Equity Research

Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 90% and 24.44%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Acadia Healthcare (ACHC) Beats Q3 Earnings Estimates

by Zacks Equity Research

Acadia Healthcare (ACHC) delivered earnings and revenue surprises of 1.11% and 0.40%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 33.33% and 13.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -540% and 24.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of -20.63% and 90.26%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inovio Pharma (INO) Stock Rallies 134% in a Month: Here's Why

by Zacks Equity Research

Inovio Pharma (INO) surges 134% in a month, mainly due to its plans to submit a regulatory application seeking approval of its lead candidate, INO-3107, in the second half of 2024 to treat RRP.

Zacks Equity Research

Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody

by Zacks Equity Research

The FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news.

Zacks Equity Research

Vericel Corporation (VCEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Vericel Corporation (VCEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Coherus (CHRS) Stock Rises on BLA Re-Filing for Udenyca Onbody

by Zacks Equity Research

Coherus (CHRS) resubmits biologics license application for Udenyca Onbody, an on-body injector presentation of Udenyca to the FDA. Stock rises.

Zacks Equity Research

Coherus (CHRS) Gets CRL for Udenyca Onbody, Shares Down

by Zacks Equity Research

Coherus (CHRS) gets CRL for the biologics license application supplement for Udenyca Onbody, an on-body injector presentation of Udenyca.

Zacks Equity Research

Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 26.92% and 15.53%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -22.95% and 36.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Coherus BioSciences (CHRS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 6.25% and 0.81%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Coherus BioSciences (CHRS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -81.13% and 20.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why Coherus BioSciences (CHRS) Looks Ripe for Bottom Fishing

by Zacks Equity Research

Coherus BioSciences (CHRS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.